Edit |   |
Antigenic Specificity | Phospho-TEK (Y1113) |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | human (predicted reactivity: bovine, zebrafish, mouse) |
Isotype | n/a |
Format | peptide affinity purified |
Size | 0.08 mL, 0.4 mL |
Concentration | vial concentration: 0.5 |
Applications | Dot Blot (DB), ELISA (EIA) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | This TEK Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1113 of human TEK. The TEK receptor tyrosine kinase is expressed almost exclusively in endothelial cells in mice, rats, and humans. This receptor possesses a unique extracellular domain containing 2 immunoglobulin-like loops separated by 3 epidermal growth factor-like repeats that are connected to 3 fibronectin type III-like repeats. The ligand for the receptor is angiopoietin-1. Defects in TEK are associated with inherited venous malformations; the TEK signaling pathway appears to be critical for endothelial cell-smooth muscle cell communication in venous morphogenesis. TEK is closely relate |
Immunogen | n/a |
Other Names | [Angiopoietin-1 receptor; Endothelial tyrosine kinase; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; hTIE2; p140 TEK; CD202b; TEK; TIE2; VMCM; VMCM1] |
Gene, Accession # | [TEK], Gene ID: 7010, NCBI: NP_000450.2, UniProt: Q02763 |
Catalog # | MBS9204459 |
Price | $165, $370 |
Order / More Info | Phospho-TEK (Y1113) Antibody from MYBIOSOURCE INC. |
Product Specific References | Cascone, I., et al., Blood 102(7):2482-2490 (2003). DeBusk, L.M., et al., Arthritis Rheum. 48(9):2461-2471 (2003). Poncet, S., et al., Neuropathol Appl Neurobiol 29(4):361-369 (2003). Lee, H.J., et al., Biochem. Biophys. Res. Commun. 304(2):399-404 (2003). Sussman, L.K., et al., Cancer Biol. Ther. 2(3):255-256 (2003). |